Pingda Ren from 5534 Havenridge Way, San Diego, CA 92130, age 55, Phone: 858 888-0420

Name / Title

Company / Classification

Phones & Addresses

Pingda Ren
Vice President Of Chemistry

Intellikine, Inc
Mfg Pharmaceutical Preparations · Nonclassifiable Establishments

10931 N Torrey Pne Rd, La Jolla, CA 92037
858 768-6500

Us Patents

Compounds And Compositions As Protein Kinase Inhibitors
view source
US Patent:

7371750, May 13, 2008
Filed:

Jul 29, 2004
Appl. No.:

10/909227
Inventors:

Taebo Sim - San Diego CA, US
Hyun Soo Lee - San Diego CA, US
Pingda Ren - San Diego CA, US
Qiang Ding - San Diego CA, US
Guobao Zhang - San Diego CA, US
Yi Liu - San Diego CA, US
Xia Wang - San Diego CA, US
Tetsuo Uno - San Diego CA, US
Bing Li - San Diego CA, US
Lintong Li - San Diego CA, US
Nathanael Schiander Gray - San Diego CA, US
Shuli You - San Diego CA, US
Assignee:

IRM LLC - Hamilton
International Classification:

A61K 31/5355
A61K 31/53
A61K 31/497
A61K 31/513
C07D 413/12
C07D 253/065
C07D 487/04
C07D 413/14
A61P 35/00
C07D 471/04
US Classification:

5142342, 514242, 51425216, 5142621, 544112, 544118, 544182, 544256, 544279, 544 81
Abstract:

The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, BCR-Abl, Bmx, c-Raf, Csk, Fes, FGFR, Flt3, Ikk, IR, JNK, Lck, Mkk, PKC, PKD, Rsk, SAPK, Syk, Trk, BTK, Src, EGFR, IGF, Mek, Ros and Tie2 kinases.

Compounds And Compositions As Protein Kinase Inhibitors
view source
US Patent:

7423038, Sep 9, 2008
Filed:

Jun 23, 2005
Appl. No.:

11/570661
Inventors:

Pingda Ren - San Diego CA, US
Xia Wang - San Diego CA, US
Nathanael Schiander Gray - Boston MA, US
Yi Liu - San Diego CA, US
Taebo Sim - Chestnuthill MA, US
Assignee:

IRM LLC (a Delaware Limited Liability Corporation) - Hamilton
International Classification:

A61K 31/5355
C07D 413/10
C07D 475/00
A61P 35/00
US Classification:

5142342, 514249, 544118, 544258
Abstract:

The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders than involve abnormal activation of the Abl, Bcr-abl, Bmx, c-RAF, CSK, Fes, FGFR3, Flt3, GSK3β, IR, JNK1α 1, JNK2α 2, Lck, MKK4, MKK6, p70S6K, PDGFRα, Rsk1, SAPK2α, SAPK2β, Syk and Trkβ kinases.

Compounds And Compositions As Protein Kinase Inhibitors
view source
US Patent:

7589101, Sep 15, 2009
Filed:

Aug 15, 2006
Appl. No.:

12/063550
Inventors:

Barun Okram - San Diego CA, US
Pingda Ren - San Diego CA, US
Nathanael S. Gray - Boston MA, US
Assignee:

IRM LLC - Hamilton
The Scripps Research Institute - La Jolla CA
International Classification:

A61K 31/407
A61K 31/4162
A61K 31/437
C07D 471/14
US Classification:

514293, 546 82
Abstract:

The invention provides a novel class of compounds of formula I, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the AbI, Bcr-AbI, Aurora-A, SGK, Tie-2, Trk-B, FGFR3, c-kit, b-RAF, c-RAF, DYRK2, Fms, Fyn and PDGFRalpha and PDGFR&bgr; kinases.

Compounds And Compositions As Protein Kinase Inhibitors
view source
US Patent:

7642255, Jan 5, 2010
Filed:

Apr 8, 2008
Appl. No.:

12/099708
Inventors:

Taebo Sim - Seoul, KR
Hyun Soo Lee - San Diego CA, US
Pingda Ren - San Diego CA, US
Qiang Ding - San Diego CA, US
Yi Liu - San Diego CA, US
Bing Li - Westborough MA, US
Lintong Li - San Diego CA, US
Xia Wang - San Diego CA, US
Tetsuo Uno - San Diego CA, US
Guobao Zhang - San Diego CA, US
Nathanael Schiander Gray - Boston MA, US
Shuli You - Shanghai, CN
Assignee:

IRM LLC - Hamilton
International Classification:

C07D 413/14
C07D 471/04
C07D 487/04
A61K 31/535
A61K 31/497
A61K 31/519
C07D 251/12
A61K 31/53
A61P 35/00
US Classification:

5142342, 514241, 51425505, 51425216, 5142641, 51425214, 5142621, 544279, 544117, 544215, 544256, 544118
Abstract:

The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, BCR-Abl, Bmx, c-Raf, Csk, Fes, FGFR, Flt3, Ikk, IR, JNK, Lck, Mkk, PKC, PKD, Rsk, SAPK, Syk, Trk, BTK, Src, EGFR, IGF, Mek, Ros and Tie2 kinases.

Compositions And Methods For Modulating C-Kit And Pdgfr Receptors
view source
US Patent:

7678792, Mar 16, 2010
Filed:

Oct 16, 2007
Appl. No.:

11/873196
Inventors:

Donatella Chianelli - San Diego CA, US
Christopher Cow - San Diego CA, US
Yun He - Shanghai, CN
Songchun Jiang - San Diego CA, US
Xiaolin Li - San Diego CA, US
Xiaodong Liu - San Diego CA, US
Zuosheng Liu - San Diego CA, US
Jon Loren - San Diego CA, US
Valentina Molteni - San Diego CA, US
Juliet Nabakka - Santee CA, US
Pingda Ren - San Diego CA, US
Taebo Sim - Seoul, KR
Xiaodong Wang - Chapel Hill NC, US
Shuli You - Shanghai, CN
Assignee:

IRM LLC - Hamilton
International Classification:

C07D 471/04
A61K 31/4375
A61K 31/497
A61K 31/501
A61K 31/5355
A61K 31/506
C07D 413/14
C07D 213/69
C07D 213/61
C07D 213/74
C07D 213/80
C07C 205/06
C07C 301/00
C07C 255/07
C07C 69/73
A61P 17/10
A61P 29/00
A61P 3/10
A61P 31/00
A61P 27/14
US Classification:

5142325, 514300, 51425304, 51425204, 5142345, 514275, 544362, 544238, 544127, 544331, 544 80, 544119, 546296, 546318, 546310, 546297, 546122, 568705, 558 44, 558410, 560 60
Abstract:

The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit, PDGFRα, PDGFRβ, CSF1R, Abl, BCR-Abl, CSK, JNK1, JNK2, p38, p70S6K, TGFβ, SRC, EGFR, trkB, FGFR3, FLT3, Fes, Lck, Syk, RAF, MKK4, MKK6, SAPK2β, BRK, KDR, c-raf or b-raf kinase, or mutant forms thereof.

Compounds And Compositions As Protein Kinase Inhibitors
view source
US Patent:

7745437, Jun 29, 2010
Filed:

Jun 9, 2005
Appl. No.:

11/628881
Inventors:

Pingda Ren - San Diego CA, US
Xia Wang - San Diego CA, US
Guobao Zhang - San Diego CA, US
Qiang Ding - San Diego CA, US
Shuli You - Shanghai, CN
Qiong Zhang - San Diego CA, US
Greg Chopiuk - San Diego CA, US
Pamela A. Albaugh - Carlsbad CA, US
Taebo Sim - San Diego CA, US
Nathanael Schiander Gray - Boston MA, US
Assignee:

IRM LLC - Hamilton
International Classification:

C07D 403/04
A61K 31/4178
US Classification:

5142358, 514249, 51425202, 51425405, 514256, 544122, 544238, 544295, 544328
Abstract:

The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, BCR-Abl, PDGF-R, trkB, c-SRC, BMX, FGFR3, b-RAF, ΣΓK, Tιε2, Λχκ, θNK2α2, MKK4, c-RAF, MKK6, SAPK2α and SAPK2β kinases.

Compounds And Compositions As Protein Kinase Inhbitors
view source
US Patent:

7846923, Dec 7, 2010
Filed:

May 11, 2007
Appl. No.:

12/299687
Inventors:

Pingda Ren - San Diego CA, US
Baogen Wu - San Diego CA, US
Guobao Zhang - San Diego CA, US
Yongping Xie - San Diego CA, US
Barun Okram - San Diego CA, US
Victor Nikulin - Carlsbad CA, US
Xia Wang - San Diego CA, US
Ha-Soon Choi - San Diego CA, US
Assignee:

IRM LLC - Hamilton
International Classification:

C07D 471/00
A61K 31/54
US Classification:

5142245, 546 82
Abstract:

The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, Bcr-Abl, Bcr-Abl(T315I), ALK, BLK, BMX, BRK, C-kit, c-RAF, CSK, c-SRC, EGFR, Fes, FGFR3, Flt3, Fms, Fyn, IGF-1R, IR, JAK(2), JAK(3), KDR, Lck, NLK, p70S6K, PDGFRα, Ros, SAPK2α, SGK, SIK, Syk, Tie2 and TrkB kinases.

Substituted Pyrrolo[2,3-D]Pyrimidines And Compositions As Protein Kinase Inhibitors
view source
US Patent:

8183248, May 22, 2012
Filed:

May 10, 2006
Appl. No.:

11/914308
Inventors:

Advait Nagle - San Diego CA, US
Nathanael Schiander Gray - Boston MA, US
Yi Liu - San Diego CA, US
Pingda Ren - San Diego CA, US
Taebo Sim - San Diego CA, US
Shuli You - Shanghai, CN
Assignee:

IRM LLC - Hamilton
International Classification:

C07D 487/04
A61K 31/519
US Classification:

5142651, 544280, 544122, 51425216, 5142328
Abstract:

The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of Abl, Bcr-Abl, Bmx, BTK, b-RAF, c RAF, CSK, cSRC, Fes, FGFR3, Flt3, IKKα, IKKβ, JNK1α1, JNK2α2, Lck, Met, MKK4, MKK6, p70S6K, PAK2, PDGFRα, PKA, PKCα, PKD2, ROCK-II, Ros, Rsk1, SAPK2α, SAPK2β, SAPK3, SAPK4, SGK, Syk, Tie2 and TrkB kinases.

Resumes

Co-Founder, President And Chief Operations Officer

view source

Location:

Washington, DC

Industry:

Biotechnology

Work:

Wellspring Biosciences - Greater San Diego Area since May 2012
Senior VP of Chemistry, Co-Founder
Intellikine (acquired by Takeda Pharmaceuticals in January 2012) Jan 2007 - Apr 2012
VP of Chemistry, Co-Founder
GNF Oct 2001 - Dec 2006
Senior Research Investigator
AMRI Feb 2001 - Oct 2001
Senior Research Chemist
State University of New York at Buffalo Oct 1997 - Jan 2001
Postdoctoral Fellow

Education:

Fudan University 1985 - 1997

Skills:

Chemistry
Drug Discovery
Drug Development
Biotechnology
Medicinal Chemistry
High Throughput Screening
Protein Chemistry
Biochemistry
Drug Design
In Vivo
Organic Chemistry
Lead Change
Purification
Molecular Biology
Lifesciences
Cell
Research
Oncology
Assay Development
Organic Synthesis
Elisa
In Vitro
Lc Ms
Cell Biology
Immunology
Cell Culture
Cancer
Pharmacology
Cheminformatics

Pingda Ren

Pingda Ren Phones & Addresses

Work

Education

Skills

Industries

Us Patents

Compounds And Compositions As Protein Kinase Inhibitors

Compounds And Compositions As Protein Kinase Inhibitors

Compounds And Compositions As Protein Kinase Inhibitors

Compounds And Compositions As Protein Kinase Inhibitors

Compositions And Methods For Modulating C-Kit And Pdgfr Receptors

Compounds And Compositions As Protein Kinase Inhibitors

Compounds And Compositions As Protein Kinase Inhbitors

Substituted Pyrrolo[2,3-D]Pyrimidines And Compositions As Protein Kinase Inhibitors

Resumes

Co-Founder, President And Chief Operations Officer